Compare GLP & TRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GLP | TRAX |
|---|---|---|
| Founded | 2005 | 2025 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil Refining/Marketing | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.9B |
| IPO Year | 2005 | 2026 |
| Metric | GLP | TRAX |
|---|---|---|
| Price | $44.18 | $47.60 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $75.17 |
| AVG Volume (30 Days) | 69.2K | ★ 716.3K |
| Earning Date | 11-06-2026 | 11-03-2026 |
| Dividend Yield | ★ 7.18% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $18,561,421,000.00 | N/A |
| Revenue This Year | $43.70 | N/A |
| Revenue Next Year | $25.83 | N/A |
| P/E Ratio | $23.28 | ★ N/A |
| Revenue Growth | ★ 8.14 | N/A |
| 52 Week Low | $39.58 | $15.69 |
| 52 Week High | $54.29 | $54.78 |
| Indicator | GLP | TRAX |
|---|---|---|
| Relative Strength Index (RSI) | 43.06 | 58.17 |
| Support Level | $41.32 | $35.11 |
| Resistance Level | $49.74 | $48.94 |
| Average True Range (ATR) | 1.82 | 3.20 |
| MACD | -0.12 | 0.15 |
| Stochastic Oscillator | 42.06 | 39.33 |
Global Partners LP is a limited partnership that acts as a midstream logistics and marketing company. It is mainly engaged in purchasing, selling, storing and logistics of transporting petroleum and related products. The company owns and operates and control terminal networks of refined petroleum products and renewable fuels in Massachusetts, Maine, Connecticut, Vermont, and other places. It distributes gasoline and gasoline blendstocks, distillates, residual oil, renewable fuels, crude oil, natural gas and propane to wholesalers, retailers and commercial customers. The company operates through three segments i.e. Wholesale, Gasoline Distribution and Station Operations and Commercial. It generates maximum revenue from the GDSO segment.
First Tracks Biotherapeutics Inc is a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. Its clinical-stage pipeline includes rosnilimab, a selective pathogenic T cell depleter, for which it completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA), ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease (CeD) and eosinophilic esophagitis (EoE), and ANB101, a BDCA2 modulator, in a Phase 1a trial. The company operates in one reportable segment focused on research and development activities to deliver immunology therapeutics for autoimmune and inflammatory diseases.